$ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Healthcare
Sector
Drug Manufacturers - Specialty & Generic
Industry
Sheldon L. Koenig
CEO
304
Employees
$2.55
Current Price
$701.23M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 3 | $102,352.23 | 37,710 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 3 | $102,352.23 | 37,710 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 3 | $102,352.23 | 37,710 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 3 | $102,352.23 | 37,710 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 4 | $107,219.92 | 39,399 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | Looker Benjamin Chief Legal Officer | Sale | 5,708 | $2.70 | $15,428.72 | View Details |
| Mar 17, 2026 | Koenig Sheldon L. Director | Sale | 25,578 | $2.72 | $69,546.58 | View Details |
| Mar 17, 2026 | Halladay Benjamin Chief Financial Officer | Sale | 6,424 | $2.71 | $17,376.92 | View Details |
| Jan 20, 2026 | Looker Benjamin General Counsel | Sale | 1,689 | $2.88 | $4,867.70 | View Details |
14 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated$0.23
Actual$0.22
Miss
Revenue
Estimated$166.12M
Actual$168.45M
Beat
EPS
Estimated$0.23
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history